✦ LIBER ✦

The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus a DPP-4 Inhibitor in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales

✍ Scribed by Charokopou, M.; McEwan, P.; Lister, S.; Callan, L.; Bergenheim, K.; Tolley, K.; Roudaut, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Cost-Effectiveness of Dapagliflozin

✍ Charokopou, M.; McEwan, P.; Lister, S.; Callan, L.; Bergenheim, K.; Tolley, K.; 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

The Cost-Effectiveness of Dapagliflozin

✍ Charokopou, M.; McEwan, P.; Lister, S.; Callan, L.; Bergenheim, K.; Tolley, K.; 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PDB37 THE COST-EFFECTIVENESS OF SAXAGLIP

✍ K Kolasa; M Niewada; J Puelles Fernandez de Troconiz; R Townsend; P McEwan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

PDB44 THE COST-EFFECTIVENESS OF SAXAGLIP

✍ W Erhardt; K Bergenheim; R Townsend; J Puelles Fernandez de Troconiz; P McEwan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

PDB40 The Importance of HbA1C Evolution

✍ Willis, M.; He, J.; Neslusan, C.; Johansen, P.; Worbes-cerezo, M. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PDB17 Comparison of Clinical and Economi

✍ Bron, M.; Chen, K.; Cheng, D.; Bensimon, A.G.; Wu, E.Q. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB